She specializes in hormone therapy, peptide therapy, and medical weight loss, using evidence-based protocols to restore metabolic function and optimize long-term health.
Research overview Related protocols and comparisons Ipamorelin (5 mg Vial) Dosage Protocol Ipamorelin (10 mg Vial) Dosage Protocol CJC-1295 NO DAC + Ipamorelin (10 mg Blend) Dosage Protocol Tesamorelin 5mg + Ipamorelin 5mg (10mg Blend) Dosage Protocol CJC-1295 DAC (2 mg) + Ipamorelin (5 mg) Stack Dosage Protocol AOD-9604 + CJC-1295 + Ipamorelin (12 mg Blend) Dosage Protocol CJC-1295 DAC (2 mg Vial) Dosage Protocol CJC-1295 DAC (5 mg Vial) Dosage Protocol
Each batch is third-party tested for quality and consistency
Alternative Names: GRF(1-29)
Abdominal obesity In a 12-month clinical trial published in 2010, which involved 404 HIV-infected patients with excess abdominal fat, the group that received 2mg of tesamorelin per day saw an 18% decrease in visceral fat compared to placebo.9 There are two things to note in order to appreciate the full scope of these findings: Visceral fat (i.e., fat accumulation around the abdominal organs) is famously stubborn and cant be burned selectively through exercise
The most common error pattern: researchers assume vial labels represent exact peptide mass when lyophilised powders routinely contain 512% overfill to compensate for handling loss
